Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 17/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993921 | 1.00 | MAPT (0.57) | MAPTGAAKDM1ATNKSTP53 | |
| SCHEMBL22134947 | 0.84 | KDM1A (0.49) | MAPTGAAKDM1ATP53MEN1 | |
| SCHEMBL1706249 | 0.81 | MAPT (0.67) | MAPTGAAKDM1ATP53MEN1 | |
| SCHEMBL28469729 | 0.78 | KDM1A (0.64) | MAPTKDM1ATP53MEN1NPC1 | |
| SCHEMBL1706301 | 0.76 | SMN1; SMN2 (0.51) | MAPTTP53MEN1NPC1KMT2A | |
| Hydrochloric Acid SCHEMBL13517466 | 0.75 | SMN1; SMN2 (0.50) | MAPTTP53MEN1NPC1KMT2A | |
| SCHEMBL1702502 | 0.75 | KDM4E (0.54) | MAPTGAANPC1KMT2A | |
| SCHEMBL2258103 | 0.75 | KDM1A (0.71) | MAPTKDM1ATP53MEN1KMT2A | |
| SCHEMBL25854283 | 0.74 | MAPT (0.45) | MAPTGAAMEN1NPC1KMT2A | |
| SCHEMBL9537343 | 0.72 | TDP1 (0.53) | MAPTGAAMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | MAPT 3932/4885GAA 4148/4885KDM1A 1321/4885 |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | MAPT 3932/4885GAA 4148/4885KDM1A 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.